Simulations Plus SLP Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Total Services | $9.66M+7.9% | $9.54M+16.2% | —— | —— | $8.95M+23.5% | |
| Total Software | $14.64M+8.5% | $8.88M-17.1% | —— | —— | $13.48M+31.5% | |
| Gross Profit by Business | ||||||
| Services | $3.16M+41.5% | $3.42M+59.7% | $2.72M— | $2.96M+7.6% | $2.23M-24.5% | |
| Software | $12.99M+19.2% | $7.47M-7.5% | $7.13M-0.7% | $10.08M-4.1% | $10.9M+6.1% | |
| Gross Margin by Business | ||||||
| Services | 33%+8.0pp | 36%+10.0pp | 1%— | 38%-3.0pp | 25%-19.0pp | |
| Software | 89%+8.0pp | 84%+9.0pp | —— | 80%-8.0pp | 81%-7.0pp | |
| Concentration risk, percentage by Business | ||||||
| Total Services | 100%0.0pp | 100%0.0pp | —— | —— | 100%— | |
| Total Software | 100%0.0pp | 100%0.0pp | —— | —— | 100%— | |
| Cost of Goods and Services Sold by Business | ||||||
| Services | $6.5M-3.2% | $6.12M+0.8% | $5.73M-37.0% | $4.79M+23.3% | $6.72M+79.8% | |
| Software | $1.65M-36.3% | $1.41M-46.5% | $1.89M-31.1% | $2.54M+81.4% | $2.59M+91.9% | |
| Goodwill, Acquired During Period by Business | ||||||
| Services | $0— | $0— | $0— | —— | —— | |
| Software | $0— | $0— | $0— | —— | —— | |
| Goodwill, Impairment Loss by Business | ||||||
| Services | $0-100% | $0-100% | $8.98M— | $8.98M— | $8.98M— | |
| Software | $0— | $0— | $571K— | —— | —— | |
| Revenue by Product | ||||||
| Clinical Operations | $415K-53.6% | $300K-82.2% | —— | —— | $894K— | |
| Commercialization | $2.28M-2.9% | $2.79M+38.7% | —— | —— | $2.35M— | |
| Development | $18.86M+12.0% | $13.97M+0.4% | —— | —— | $16.85M— | |
| Discovery | $2.73M+16.6% | $1.36M+4.0% | —— | —— | $2.34M— | |
| Total cost of revenues by Product | ||||||
| Services | $6.5M-3.2% | $6.12M+0.8% | $5.73M-37.0% | $4.79M+23.3% | $6.72M+79.8% | |
| Software | $1.65M-36.3% | $1.41M-46.5% | $1.89M-31.1% | $2.54M+81.4% | $2.59M+91.9% | |
| Concentration risk, percentage by Product | ||||||
| Clinical Operations | 3%-4.0pp | 3%-13.0pp | —— | —— | 7%— | |
| Commercialization | 23%-2.0pp | 29%+4.0pp | —— | —— | 25%— | |
| Development | 155%+5.0pp | 153%+6.0pp | —— | —— | 150%— | |
| Discovery | 19%+2.0pp | 15%+3.0pp | —— | —— | 17%— | |
| Revenue by Geography | ||||||
| Americas | $16.58M+2.9% | $13.45M-7.1% | $12.58M-14.4% | $14.54M+17.0% | $16.11M+29.3% | |
| Asia Pacific | $1.76M+16.0% | $1.84M+6.1% | $1.92M+38.9% | $2.12M+32.3% | $1.51M+28.4% | |
| EMEA | $5.96M+23.9% | $3.14M+15.3% | $2.97M+14.5% | $3.7M-18.1% | $4.81M+3.0% | |
| Concentration risk, percentage by Geography | ||||||
| Americas | 68%-4.0pp | 73%-3.0pp | —— | 71%+4.0pp | 72%+4.0pp | |
| Asia Pacific | 7%0.0pp | 10%0.0pp | —— | 11%+2.0pp | 7%+1.0pp | |
| EMEA | 25%+4.0pp | 17%+3.0pp | —— | 18%-6.0pp | 21%-4.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Simulations Plus break its business down?
- Simulations Plus (SLP) reports revenue by business across 2 parts — Total Services and Total Software. Each is extracted from the segment footnotes and tracked over time.
- Where does Simulations Plus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Simulations Plus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
